SDU RIO | Interim Business Development | Blood analysis | Spin-out | External Innovation
Hemove is an innovation which enables clinical decision making on hemolyzed blood samples. Hemove removes the hemolysis effect. The innovation is a novel blood reagent, formulation and application.
As interim business developer in the SDU RIO Commercialization team our was to build and optimize the corporate partnering presentation material for Hemove.
Completing the task included:
• Researched prior SDU RIO work completed on the project
• Researched and quantified the unique value proposition of Hemove for both hospitals and analysis technology/service providers
• Researched & quantified the hemolysis problem in clinical settings
• Researched & quantified the expected positive clinical impact of Hemove
• Researched & quantified the expected hospital cost saving impact of Hemove
• Visualized Hemove implementation options (automatic, semi-automatic, point-of-care)
• Built and optimized slide deck for corporate partnering